We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

56 hedge funds and large institutions have $20.3M invested in Matinas BioPharma in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

0.02% less ownership

Funds ownership: 0.25% → 0.23% (-0.02%)

15% less funds holding

Funds holding: 66 → 56 (-10)

26% less capital invested

Capital invested by funds: $27.4M → $20.3M (-$7.09M)

59% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 17

Holders
56
Holders Change
-10
Holders Change %
-15.15%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
9
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAG
Private Advisor Group
New Jersey
+$65.9K
2
State Street
State Street
Massachusetts
+$38.9K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$32.3K
4
BlackRock
BlackRock
New York
+$21.8K
5
Jane Street
Jane Street
New York
+$11.4K

Top Sellers

Rank Fund Capital Flow
1
CCM
Courage Capital Management
Tennessee
-$662K
2
Truist Financial
Truist Financial
North Carolina
-$207K
3
SWM
Spire Wealth Management
Virginia
-$163K
4
DA
DCF Advisers
Connecticut
-$156K
5
Citadel Advisors
Citadel Advisors
Florida
-$119K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
26
Osaic Holdings
Arizona
$25K – – –
MA
27
MONECO Advisors
Connecticut
$24K – – –
DAS
28
Dynamic Advisor Solutions
Arizona
$24K +$3.06K +83 +16%
Commonwealth Equity Services
29
Commonwealth Equity Services
Massachusetts
$23K – – –
Victory Capital Management
30
Victory Capital Management
Texas
$20K -$589 -16 -3%
IWC
31
Integrated Wealth Concepts
Massachusetts
$20K – – –
RJA
32
Raymond James & Associates
Florida
$18K +$6.26K +170 +63%
Wells Fargo
33
Wells Fargo
California
$17K – – –
NRS
34
Neville Rodie & Shaw
New York
$14K – – –
SBWIC
35
Schaper Benz & Wise Investment Counsel
Wisconsin
$12K +$147 +4 +1%
Kovitz Investment Group Partners
36
Kovitz Investment Group Partners
Illinois
$12K +$11K +300 New
Jane Street
37
Jane Street
New York
$12K +$11.4K +310 New
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$11K +$4.42K +120 +84%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$10K -$15.9K -431 -63%
AWM
40
AE Wealth Management
Kansas
$10K – – –
CG
41
Clarus Group
Texas
$10K – – –
JWCA
42
J.W. Cole Advisors
Florida
$9K – – –
BJL
43
Brighton Jones LLC
Washington
$8K – – –
CFS
44
CRA Financial Services
New Jersey
$8K – – –
FAIM
45
Financial Advocates Investment Management
Washington
$8K – – –
FC
46
Fore Capital
New York
$8K – – –
Fidelity Investments
47
Fidelity Investments
Massachusetts
$6K +$5.45K +148 New
TRCT
48
Tower Research Capital (TRC)
New York
$5K +$4.12K +112 New
Bank of America
49
Bank of America
North Carolina
$3K -$105K -2,854 -98%
HFM
50
Hartford Financial Management
Connecticut
$2K – – –
1
2
3

MTNB Hedge Fund Activity: Q1 2022 in Review

56 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2022, worth a combined $20.3M — down 26% from $27.4M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of MTNB and 7 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 10 added.

The largest buyer was Private Advisor Group, adding an estimated $65.9K. The largest seller was Courage Capital Management, cutting an estimated $662K.

  • 56 institutional investors held Matinas BioPharma (MTNB) as of Q1 2022, down from 66 in Q4 2021.
  • Funds reported $20.3M of Matinas BioPharma stock for Q1 2022, down 26% quarter-over-quarter.
  • 7 funds opened new Matinas BioPharma positions in Q1 2022 and 17 closed out, a net change of -10 holders.
  • The largest Matinas BioPharma buyer in Q1 2022 was Private Advisor Group, an estimated $65.9K added.
  • The largest Matinas BioPharma seller in Q1 2022 was Courage Capital Management, an estimated $662K sold.

Based on aggregated 13F filings for Q1 2022.